{ "Open-Label Extension Study of ORKA-001 for Plaque Psoriasis", "This study is an extension for people who have already participated in an Oruka Therapeutics study for plaque psoriasis. It's testing the long-term safety of a drug called ORKA-001, given by injection under the skin (subcutaneous injection). The main goal is to see how often side effects happen over a long period, up to 144 weeks. You can join if you are 18 or older, have plaque psoriasis, and have completed a previous Oruka Therapeutics study. The study plans to enroll about 240 participants.", "design": "This is an open-label extension study, meaning both you and the study team will know you are receiving ORKA-001. It plans to include about 240 participants.", "commitments": "You would receive ORKA-001 injections for up to approximately 96 weeks. You would also have follow-up visits for about 48 weeks after your last treatment.", "compensation": "Not stated in the trial record.", "follow_up": "You will be followed for about 48 weeks after your last study visit, for a total of up to 144 weeks from the start of the study.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.